BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29576383)

  • 1. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
    Akin S; Dizdar O; Karakas Y; Turker A; Kars A
    Curr Probl Cancer; 2018; 42(3):344-349. PubMed ID: 29576383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
    Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
    Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
    Minobe S; Todo Y; Suzuki Y; Aoyagi Y; Umazume T; Okamoto K; Kato H
    J Obstet Gynaecol Res; 2011 Jun; 37(6):645-9. PubMed ID: 21375676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
    Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
    Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
    Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma.
    Hawkins RE; Wiltshaw E; Mansi JL
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S26-9. PubMed ID: 2347045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
    Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.
    Pearl ML; Inagami M; McCauley DL; Valea FA; Chalas E; Fischer M
    Int J Gynecol Cancer; 2002; 12(6):745-8. PubMed ID: 12445253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas.
    Piura B; Rabinovich A
    Eur J Gynaecol Oncol; 2005; 26(3):275-8. PubMed ID: 15991525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity.
    Chowdhary M; Sen N; Jeans EB; Miller L; Batus M; Gitelis S; Wang D; Abrams RA
    Am J Clin Oncol; 2019 Jan; 42(1):1-5. PubMed ID: 29782358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
    Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
    Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic uterine leiomyosarcomas: a single-institution experience.
    Bernstein-Molho R; Grisaro D; Soyfer V; Safra T; Merimsky O
    Int J Gynecol Cancer; 2010 Feb; 20(2):255-60. PubMed ID: 20134269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide and doxorubicin combination chemotherapy for recurrent nasopharyngeal carcinoma patients.
    Dede DS; Aksoy S; Cengiz M; Gullu I; Altundag K
    Asian Pac J Cancer Prev; 2012; 13(5):2225-8. PubMed ID: 22901198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
    Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone.
    Pautier P; Rey A; Haie-Meder C; Kerbrat P; Dutel JL; Gesta P; Bryard F; Morice P; Duvillard P; Lhommé C
    Int J Gynecol Cancer; 2004; 14(6):1112-7. PubMed ID: 15571617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing JA; Malfetano JH
    Gynecol Oncol; 1996 Aug; 62(2):226-9. PubMed ID: 8751554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment and prognosis of stage IV alveolar soft part sarcoma].
    Zhao J; Yang Y
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):932-6. PubMed ID: 23336381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study.
    Jäger E; Klein O; Wächter B; Bernhard H; Dippold W; Meyer zum Büschenfelde KH; Knuth A
    Oncology; 1996; 53(1):58-63. PubMed ID: 8570133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.